BMRN – biomarin pharmaceutical inc. (US:NASDAQ)
Stock Stats
News
4/17
06:05 pm
bmrn
Low
BioMarin Pharmaceutical (BMRN) was downgraded by Weiss Ratings from "hold (c-)" to "sell (d+)".
4/15
01:03 pm
bmrn
Low
BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy [Seeking Alpha]
4/1
06:04 pm
bmrn
Medium
BioMarin Pharmaceutical (BMRN) was upgraded by Weiss Ratings from "sell (d+)" to "hold (c-)".
3/31
03:33 am
bmrn
Medium
Here is Why BioMarin (BMRN) is Projected to Rally [Yahoo! Finance]
3/30
07:26 am
bmrn
Low
BioMarin Pharmaceutical Inc. (BMRN) Rated Overweight at Wells Fargo Despite Voxzogo Phase 2 Study Discontinuations [Yahoo! Finance]
2/23/2026
04:05 pm
BMRN
-0.5%
BEAT
10/27/2025
04:03 pm
BMRN
1.6%
MISS
8/4/2025
04:02 pm
BMRN
2.7%
BEAT
5/1/2025
04:05 pm
BMRN
-1.1%
BEAT
3/16
12:08 pm
Reiterates
Outperform
Outperform
Wolfe Research
Low
-0.1%
3/16
12:08 pm
Reiterates
Outperform
Outperform
Wolfe Research
Low
-0.1%
3/4
09:36 am
Maintains
Overweight
Overweight
Barclays
Low
2.7%
3/4
09:36 am
Maintains
Overweight
Overweight
Barclays
Low
2.7%
3/3
07:18 am
Reiterates
Overweight
Overweight
Barclays PLC
Low
-0.1%
3/26
04:10 pm
bmrn
Low
Form SCHEDULE 13G/A BIOMARIN PHARMACEUTICAL Filed by: VANGUARD GROUP INC
3/19
04:53 pm
bmrn
Low
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 18 Filed by: Davis George Eric
3/19
04:51 pm
bmrn
Low
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 17 Filed by: Guyer Charles Greg
3/19
04:49 pm
bmrn
Low
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 17 Filed by: Mueller Brian
3/19
04:34 pm
bmrn
Low
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 17 Filed by: Hardy Alexander
Show more
Top News Gainers
5/14 Form 4 BIOMARIN PHARMACEUTICAL For: May 10 Filed by: BIENAIME JEAN JACQUES 7.5%
2/20 BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020 6.0%
3/24 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "outperform" rating re-affirmed by analysts at Wedbush. 5.4%
3/3 Coronavirus Correction Watchlist: 11 More Stocks [Investor's Business Daily] 5.0%
4/9 Form 4 BIOMARIN PHARMACEUTICAL For: Apr 08 Filed by: Ajer Jeffrey Robert 4.3%
12/14 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $120.00 price target on the stock. 4.2%
7/9 BioMarin Appoints Pharmaceutical Veteran and Former J & J Executive, Liz McKee Anderson, to Board of Directors 3.4%
4/13 Form 4 BIOMARIN PHARMACEUTICAL For: Apr 09 Filed by: BIENAIME JEAN JACQUES 3.3%
3/1 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $164.00 price target on the stock. 3.2%
12/12 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Bank of America Corp. They now have a $90.00 price target on the stock. 2.9%
Top News Decliners
3/11 Form 4 BIOMARIN PHARMACEUTICAL For: Mar 03 Filed by: BIENAIME JEAN JACQUES -12.3%
5/28 BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe -7.9%
4/6 BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe -5.4%
4/15 Biomarin Could Possibly Be The First To Obtain FDA Approval For Hemophilia Gene Therapy Treatment [Seeking Alpha] -5.3%
3/17 Form 4 BIOMARIN PHARMACEUTICAL For: Mar 13 Filed by: BAFFI ROBERT -4.8%
4/30 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -4.2%
3/16 Why BioMarin Pharmaceutical, Bristol-Myers Squibb, and bluebird bio Are Getting Hammered Monday [The Motley Fool] -4.1%
1/11 These 3 Biotech Stocks Could Be Top Stocks in 2020 [The Motley Fool] -4.1%
10/1 BioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York -3.9%
5/1 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $108.00 price target on the stock. -3.9%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3